Stem Cell Therapeutics Inc., Transition Therapeutics deal

TTH completed the previously announced acquisition of the remaining 54% of Stem Cell Therapeutics it did not already own (see BioCentury, Jan. 20). TTH issued 2.8 million shares valued at C$840,000 (U...